Among the various therapeutic targets explored, c-Met, a receptor tyrosine kinase activated by hepatocyte growth factor (HGF) has shown particular promise [7] While HGF/c-Met signaling is essential for normal liver development and repair, [8–11] its dysregulation drives HCC initiation and progression [12–15]. This evidence concerns the gene MET and hepatocellular carcinoma.